ProShare Advisors
DFTX

ProShare Advisors’s Definium Therapeutics DFTX Stock Holding History

ProShare Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$354K Sell
18,731
-2,808
-13% -$47.7K ﹤0.01% 1253
2025
Q4 		$288K Buy
21,539
+5,947
+38% +$73.6K ﹤0.01% 1483
2025
Q3 		$184K Sell
15,592
-2,676
-15% -$25K ﹤0.01% 1710
2025
Q2 		$119K Sell
18,268
-941
-5% -$6.19K ﹤0.01% 1846
2025
Q1 		$112K Sell
19,209
-6,958
-27% -$49.8K ﹤0.01% 1813
2024
Q4 		$182K Buy
26,167
+12,562
+92% +$86.4K ﹤0.01% 1914
2024
Q3 		$77.4K Buy
+13,605
New +$94.6K ﹤0.01% 1922
2022
Q2 		– Sell
-4,026
Closed -$67K – 1995
2022
Q1 		$67K Sell
4,026
-1,041
-21% -$18.1K ﹤0.01% 2089
2021
Q4 		$105K Buy
5,067
+2,094
+70% +$66.8K ﹤0.01% 2196
2021
Q3 		$104K Sell
2,973
-2,597
-47% -$112K ﹤0.01% 1909
2021
Q2 		$288K Buy
+5,570
New +$292K ﹤0.01% 1923

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ProShare Advisors's DFTX Position: Q1 2026 in Review

ProShare Advisors reduced its Definium Therapeutics (DFTX) stake by 13% in Q1 2026, selling an estimated $47.7K and leaving 18,731 shares worth $354K. The position accounts for ﹤0.01% of the portfolio, ranked #1253.

ProShare Advisors first reported a position in DFTX in Q2 2021 and has held it in 11 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • ProShare Advisors held 18,731 shares of Definium Therapeutics worth $354K as of Q1 2026.
  • ProShare Advisors sold 2,808 Definium Therapeutics shares in Q1 2026, an estimated $47.7K.
  • Definium Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1253 holding.
  • ProShare Advisors first reported a position in Definium Therapeutics in Q2 2021 and has held it in 11 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.